Test Price
2,800 AED✅ Home Collection Available
ZEB2 Gene Sequencing (NGS) for Congenital Central Hypoventilation Syndrome – 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
The ZEB2 gene sequencing test delivers a molecular diagnosis for congenital central hypoventilation syndrome (CCHS) and Mowat-Wilson syndrome with 99.9% analytical sensitivity. This targeted next-generation sequencing (NGS) assay covers the entire coding region plus ±20 bp intronic boundaries, confirmed by Sanger validation on every reported variant. The test is processed under ISO 9001:2015 accreditation within a DHA-licensed facility.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test clinical guidance included in result interpretation.
- Insurance Verification: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
ZEB2 gene sequencing uses targeted NGS to identify pathogenic variants across all coding exons and flanking intronic regions of the ZEB2 gene. The assay detects single-nucleotide variants, small insertions and deletions, and splice-site alterations that cause CCHS and Mowat-Wilson syndrome. Sanger sequencing validates all reported findings, ensuring a 99.9% positive predictive value. This single-gene approach delivers faster results and lower cost compared to whole exome sequencing while maintaining full gene coverage.
| Feature | Our Test (ZEB2 Single-Gene NGS) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 99.9% analytical sensitivity with full gene coverage (±20 bp intronic boundaries) | ≈95% coverage of ZEB2 coding exons, often with gaps in high-GC regions |
| Method | Targeted NGS with Sanger validation of all reported variants | Exome capture + NGS, may miss deep intronic and copy number variants |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
| Cost in UAE | 2,800 AED | 4,500–6,000 AED |
Physician Insight & Safety Protocols
“ZEB2 sequencing is a critical tool for confirming a suspected diagnosis of congenital central hypoventilation syndrome, but it must always be integrated with the patient's respiratory pattern, dysmorphic evaluation, and family history. A negative result does not exclude the diagnosis if clinical suspicion remains high; in such cases, consider alternative tissue testing or broader genomic analysis. Early molecular confirmation enables timely multidisciplinary intervention and improves long-term neurodevelopmental outcomes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory on Medication & Clinical Management
Do not alter or discontinue any prescribed respiratory support, ventilator settings, or medication regimen based solely on genetic test results. All management decisions must be made by the supervising physician in the context of the full clinical picture. Genetic testing is a diagnostic adjunct, not a substitute for acute clinical care.
Safety Exclusion Criteria & Emergency Red Flags
- Testing is not recommended for asymptomatic minors without explicit informed parental consent and pre-test genetic counseling, as mandated by UAE federal regulations.
- This peripheral blood-based NGS assay may not detect low-level somatic mosaicism; if clinical suspicion remains high despite a negative result, consultation with a medical geneticist about alternative tissue testing is advised.
- Emergency Red Flags: Sudden respiratory distress, prolonged apnea, cyanosis, or oxygen desaturation below 90% require immediate emergency department evaluation. Do not delay emergency care while awaiting genetic results.
Patient FAQ & Clinical Guidance
1. What is the purpose of ZEB2 gene sequencing?
ZEB2 gene sequencing identifies disease-causing variants in the ZEB2 gene, confirming a molecular diagnosis of congenital central hypoventilation syndrome (CCHS) and Mowat-Wilson syndrome with 99.9% diagnostic accuracy. This test is ordered when a child or adult presents with unexplained central hypoventilation, characteristic dysmorphic features, or a family history suggestive of these conditions.
2. How is the sample collected and what is the turnaround time?
A standard peripheral blood draw (2–5 mL in EDTA tube) is collected by our certified mobile phlebotomy team at your home between 8 AM and 11 PM daily, under temperature-controlled cold-chain logistics. Alternatively, a buccal swab or pre-extracted DNA sample may be accepted after consultation with our genetics laboratory. Results are reported within 3 to 4 weeks from sample receipt.
3. Is this test covered by insurance in the UAE?
Many UAE health insurance plans cover genetic testing for congenital central hypoventilation syndrome when deemed medically necessary by a physician. To verify your direct billing eligibility, send a clear photo of your insurance card via WhatsApp to +971 54 548 8731. Our billing team will confirm coverage within 24 hours.
4. What should I do if I receive a positive result?
A positive result should be discussed with your referring physician and a board-certified medical geneticist. We provide telephonic post-test clinical guidance to help interpret the report, understand recurrence risks, and coordinate multidisciplinary care including pulmonology, neurology, and developmental pediatrics. Genetic counseling for family members is strongly recommended.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within the UAE. Patient consent for genetic testing follows the standards set by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 accreditation and is licensed by the Dubai Health Authority under DHA Facility License No. 1143.
Support & Booking: +971 54 548 8731 | Home Collection: 8 AM – 11 PM daily.
Clinical & Logistical Metadata
| Test Name | ZEB2 Gene Sequencing (NGS) for Congenital Central Hypoventilation Syndrome |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (21–28 calendar days) |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube), buccal swab, or pre-extracted genomic DNA; VIP mobile phlebotomy and cold-chain home collection available |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with Sanger confirmation of all clinically significant variants |
| ICD-10-CM Code | G47.35, Q87.89 |
| LOINC Code | 97179-1 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians